Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This article outlines treatment options and counseling recommendations for pediatric alopecia areata, highlighting shared decision-making based on disease severity and patient goals, with newer treatments like JAK inhibitors and dupilumab requiring attention to cost and side effects.

This study focused on developing a nanoemulsion-based gel for delivering minoxidil, aiming to enhance its contact time with the scalp and potentially improve skin absorption compared to conventional topical solutions.

Minoxidil, when used with a diuretic and β-blocking agent, can safely lower blood pressure in most children with severe hypertension due to kidney disease, with minimal side effects.

This study found that combining oral chelated Zinc with 5% minoxidil solution improved hair density and hair shaft diameter in women with female pattern hair loss, without reported side effects.

In this study, once-daily 5% minoxidil foam and twice-daily 2% minoxidil solution both promoted hair regrowth in women with female pattern hair loss, but noninferiority of the foam was not established.

In this study, both 5% minoxidil foam and 5% minoxidil liquid solution effectively improved hair diameter and density in male patients with androgenetic alopecia over 12 weeks, with the foam formulation showing a slight advantage in patient satisfaction and hair density gain.

This paper argues that androgenetic alopecia in transgender and gender-diverse individuals is clinically significant, suggesting individualized and gender-affirming treatment approaches, with oral minoxidil as a key therapy.

This review highlights available treatments for frontal fibrosing alopecia, noting that 5-alpha reductase inhibitors, intralesional steroids, and hydroxychloroquine currently have the most evidence supporting their use, while other treatments show variable results and require further study.

This study reported the preparation of stable oil-in-water nanoemulsions that effectively incorporate ceramide-like molecules and minoxidil, suggesting these formulations may enhance distribution and availability of hydrophobic compounds in cosmetic applications.

Topical corticosteroids are recommended first for treating pediatric alopecia areata due to safety and ease of use.

This review discusses the current therapeutic options for female pattern hair loss and emphasizes the need for managing patient expectations of permanent regrowth, reporting no new clinical results.

This article reviews advancements in hair restoration, highlighting improvements in surgical techniques and patient satisfaction, but reports no new clinical results.

This article reviews treatment options for male androgenetic alopecia, including minoxidil, 5 alpha reductase inhibitors, and hair transplantation, but reports no new clinical findings.

This review highlights current treatment options for frontal fibrosing alopecia, noting that 5-α-reductase inhibitors, intralesional steroids, and hydroxychloroquine have the highest evidence of effectiveness, while other therapies show variable results and need further research.

This text provides contact information and no new research findings are reported.

This Cochrane Review protocol aims to evaluate the effectiveness and safety of various treatments for alopecia areata through a network meta-analysis, but no specific study findings are reported yet.

This article reviews emerging mechanobiological strategies like electrical stimulation and microneedling combined with nanotechnology as non-invasive methods for hair loss treatment, suggesting these approaches could provide futuristic alternatives to current therapies such as minoxidil, finasteride, and hair transplants.

This review identifies specific personal care products and allergens commonly causing allergic contact dermatitis in men, which may improve diagnosis and treatment.

This study evaluated the effects of different treatments, including a topical mixture of finasteride and minoxidil, PRP infiltrations, and oral medication, on hair loss, density, and follicle diameter.

This review discusses current treatment methods for managing androgenetic alopecia in men and women, but reports no new clinical results, highlighting the lack of a standard treatment guide.

This systematic review reported that gender-affirming hormone therapy may lead to changes in hair growth patterns, with differing effects for transgender men and women, potentially impacting quality of life.

This review proposes a combination treatment scheme with a rotational approach for managing androgenetic alopecia, drawing on evidence for effectiveness, long-term use convenience, and patient acceptance, but presents no new clinical results.

This review discusses recent clinical trials on the use of platelet rich plasma for treating androgenetic alopecia and reports mixed findings on its effectiveness compared to standard treatments.

This review discusses the treatment options for male androgenetic alopecia, including FDA-approved therapies and new possibilities, but reports no new clinical results.

This review discusses current concepts in hair transplantation, emphasizing the importance of patient consultation and alternative therapies like finasteride and minoxidil, but does not report new experimental findings.

Telogen Effluvium is a hair loss condition where treatment involves identifying and managing its triggers.

The document recommends personalized, culturally sensitive treatments to rejuvenate the aging Asian face, focusing on natural results and specific techniques for skin, hair, and facial features.

This commentary highlights that transgender patients are often dissatisfied with standard hormone replacement therapy for hair-related goals, emphasizing the need for dermatologists to provide informed guidance and tailor treatments.

Minoxidil can cause skin allergy; use alternative solvents or treatments if allergic.

This study found that 12 months of minoxidil treatment increased hair density and thickness in women with androgenetic alopecia, while alfatradiol primarily stabilized hair loss.